<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463305</url>
  </required_header>
  <id_info>
    <org_study_id>13-3054</org_study_id>
    <secondary_id>UL1TR001082</secondary_id>
    <nct_id>NCT02463305</nct_id>
  </id_info>
  <brief_title>Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)</brief_title>
  <official_title>Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study plans to learn more about the effects that creatine monohydrate has on disease&#xD;
      activity in ulcerative colitis. Creatine is a substance that is naturally produced by the&#xD;
      body and is found in foods, such as meat and fish. Creatine helps to provide energy to some&#xD;
      body tissues, such as the colon. In the colon, this energy allows cells to form a tight&#xD;
      barrier between molecules in digested food and bacteria and the body's infection-fighting&#xD;
      cells within the colon underneath this barrier. If the barrier becomes &quot;leaky&quot; molecules may&#xD;
      pass through and lead to inflammation. This &quot;leakiness&quot; may contribute to the colon&#xD;
      inflammation seen in ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in endoscopic assessment of mucosal inflammation in ulcerative colitis.</measure>
    <time_frame>8 weeks</time_frame>
    <description>As defined by the Mayo endoscopic score for ulcerative colitis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response in ulcerative colitis disease activity.</measure>
    <time_frame>8 weeks</time_frame>
    <description>As defined by the Mayo composite score for ulcerative colitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intestinal permeability</measure>
    <time_frame>8 weeks</time_frame>
    <description>As measured by urinary saccharide excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient symptom severity</measure>
    <time_frame>8 weeks</time_frame>
    <description>As measured by inflammatory bowel disease questionnaire (IBDQ), simple Crohn's and colitis activity index (SCCAI), and Mayo composite scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonic inflammation</measure>
    <time_frame>8 weeks</time_frame>
    <description>As assessed by fecal calprotectin, CRP, and histologic scoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine kinase modulation</measure>
    <time_frame>8 weeks</time_frame>
    <description>As assessed by CK transcript and protein in colonic tissue and serum levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical remission of ulcerative colitis disease activity.</measure>
    <time_frame>8 weeks</time_frame>
    <description>As defined by the Mayo composite score for ulcerative colitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatine modulation</measure>
    <time_frame>8 weeks</time_frame>
    <description>As defined by colonic tissue and serum levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 patients with mild-moderate ulcerative colitis treated with creatine monohydrate 21 grams per day in three divided doses taken with water for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 patients with mild-moderate ulcerative colitis treated with placebo (matching creatine monohydrate) 21 grams per day in three divided doses taken with water for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional Open-Label Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 6 patients, who were randomized to the placebo arm, will be given the option to continue with open-label creatine monohydrate treatment at 21 grams per day in three divided doses, taken with water, for 8 weeks. Only non-invasive testing will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creatine monohydrate</intervention_name>
    <description>21 grams creatine monohydrate total per day</description>
    <arm_group_label>Optional Open-Label Treatment arm</arm_group_label>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>7 grams of dextrose dissolved in 500mL water, taken three times daily</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>Dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18-70 years old with mild- to moderately-active UC that&#xD;
             extends at least 15 cm proximal to the anal verge (i.e. not proctitis) as defined by a&#xD;
             Mayo Score of 3-10, with an endoscopic subscore ≥ 1.&#xD;
&#xD;
          -  Allowed concomitant medications will include mesalamine compounds if used for at least&#xD;
             8 weeks and at a stable dose for at least 4 weeks, as well as thiopurines&#xD;
             (azathioprine, 6-mercaptopurine) if used at a stable dose for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal baseline laboratory tests:&#xD;
&#xD;
               -  Albumin &lt; 3.0 g/dL&#xD;
&#xD;
               -  ALT, AST, total bilirubin, or alkaline phosphatase &gt; 1.5 x ULN&#xD;
&#xD;
               -  Potassium &lt; 3.0 mmol/L or &gt; 5.5 mmol/L&#xD;
&#xD;
               -  Creatinine or cystatin C &gt; ULN&#xD;
&#xD;
               -  WBC ≤ 3000&#xD;
&#xD;
               -  Platelets ≤ 105&#xD;
&#xD;
               -  Hemoglobin ≤ 10g/dL&#xD;
&#xD;
               -  Positive stool test for Clostridium difficile, ova and parasites, or routine&#xD;
                  stool culture&#xD;
&#xD;
          -  Pregnancy (as confirmed by urine pregnancy test at study outset), stated desire to&#xD;
             become pregnant during the study period, or refusal/inability to use effective methods&#xD;
             of contraception during the study period.&#xD;
&#xD;
          -  Concomitant major comorbidities (renal, hepatic, cardiac, pulmonary or malignancy) to&#xD;
             include any medical conditions requiring therapeutic anti-coagulation or anti-platelet&#xD;
             therapy.&#xD;
&#xD;
          -  Diagnosis of severe UC (Mayo Score &gt; 10)&#xD;
&#xD;
          -  Evidence or history of toxic megacolon&#xD;
&#xD;
          -  Patients who received anti-TNF agents within 3 months of screening, or who used oral&#xD;
             or rectal corticosteroids within 4 weeks of screening will be excluded.&#xD;
&#xD;
          -  Use of over-the-counter herbal or dietary supplements (excluding vitamin and minerals)&#xD;
             two weeks prior to or during the study period.&#xD;
&#xD;
          -  Use of known nephrotoxic medications (including non-steroidal anti-inflammatory drugs&#xD;
             (NSAIDs), cyclosporin A, tacrolimus, aminoglycoside antibiotics, diuretics,&#xD;
             angiotensin converting enzyme (ACE) inhibitors, or angiotensin receptor blockers) 2&#xD;
             weeks prior to or during the study period&#xD;
&#xD;
          -  Prior surgical bowel resections (excluding appendectomy)&#xD;
&#xD;
          -  Local or systemic complications or other pathological states requiring therapy with&#xD;
             corticosteroids and/or immunosuppressive agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Gerich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado Denver, Division of Gastroenterology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucy Smigiel, MPH</last_name>
    <phone>3037249143</phone>
    <email>lucy.smigiel@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Boimbo, MPH</last_name>
    <phone>303-724-8892</phone>
    <email>sandra.boimbo@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>June 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colitis, ulcerative</keyword>
  <keyword>Inflammatory bowel diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

